These data raise the intriguing potential to directly track the impact of NAFLD associated changes on CYP and UGT mediated drug clearance using EV-derived biomarkers, and account for variability in exposure, which can impact drug efficacy and tolerability [49,50,51]. This evidence concerns the gene SLC35A2 and metabolic dysfunction-associated steatotic liver disease.